Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Galmed Pharmaceutica (GLMD)

Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,704
  • Shares Outstanding, K 1,654
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,520 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 0.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.25
  • Growth Rate Est. (year over year) +44,500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7449 +38.27%
on 11/20/25
1.5399 -33.11%
on 11/17/25
-0.1200 (-10.43%)
since 11/12/25
3-Month
0.7449 +38.27%
on 11/20/25
1.6500 -37.58%
on 10/07/25
-0.4800 (-31.79%)
since 09/12/25
52-Week
0.7449 +38.27%
on 11/20/25
3.6100 -71.47%
on 01/03/25
-1.7850 (-63.41%)
since 12/12/24

Most Recent Stories

More News
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Late Breaking Abstract titled " Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramchol...

GLMD : 1.0300 (unch)
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the...

GLMD : 1.0300 (unch)
Galmed Issues CEO Letter to Shareholders

TEL AVIV, Israel , Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic,...

GLMD : 1.0300 (unch)
Galmed Pharmaceuticals: Q3 Earnings Snapshot

Galmed Pharmaceuticals: Q3 Earnings Snapshot

GLMD : 1.0300 (unch)
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

TEL AVIV, Israel , Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic,...

GLMD : 1.0300 (unch)
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tablets...

GLMD : 1.0300 (unch)
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

RAMAT-GAN, Israel , Nov. 17, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases...

GLMD : 1.0300 (unch)
Galmed Pharmaceuticals: Q2 Earnings Snapshot

Galmed Pharmaceuticals: Q2 Earnings Snapshot

GLMD : 1.0300 (unch)
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

TEL AVIV, Israel , Aug. 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic...

GLMD : 1.0300 (unch)
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

TEL AVIV, Israel , Aug. 25, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of...

GLMD : 1.0300 (unch)

Business Summary

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel.

See More

Key Turning Points

3rd Resistance Point 1.1247
2nd Resistance Point 1.0997
1st Resistance Point 1.0649
Last Price 1.0300
1st Support Level 1.0051
2nd Support Level 0.9801
3rd Support Level 0.9453

See More

52-Week High 3.6100
Fibonacci 61.8% 2.5155
Fibonacci 50% 2.1774
Fibonacci 38.2% 1.8394
Last Price 1.0300
52-Week Low 0.7449

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar